StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
002173.SZ$17.79+3.25%
Fair $17.79+0.0%

002173.SZ

Innovative Medical Management Co.,Ltd.

Consumer Cyclical / Luxury GoodsShenzhen

$17.79

+0.56 (+3.25%)

Fairly Valued+0.0%Fair Value $17.79Fund rank 32/100 · Data gapFallback financials|
SA 30/D
F-Score: 4/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 23%

FCF escenarios

weak_data · normalized FCF $-54.3M · quality 66.7/100

Data gap 32/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 36/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

30/100

D

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -2.0%, below the 5% threshold
Thesis & Journal · 002173.SZLocal privado en este navegador · Innovative Medical Management Co.,Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$7.9B

P/E

N/A

•

EV/EBITDA

105.9x

↑

ROE

-2.0%

↓

Gross Margin

6.9%

↓

Debt/Equity

0.05

↓
52-Week Range$18
$10$38

TradingView lightweight chart

002173.SZ price, volumen y niveles de valoración

Último $17.23Periodo +37.5%
Fair value: $17.79

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+3.3%

FCF CAGR

—

FCF margin

-1.1%

FCF / Net income

0.25x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $781.3M · net income $-34.9M · FCF $-8.6M

2022-FY → 2025-FY

Gross margin

6.9%+2.6% pts

Operating margin

-8.9%+4.0% pts

Net margin

-4.5%+5.9% pts

FCF margin

-1.1%+19.7% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$781.3M$781.3M$816.0M$805.6M$709.7M
Net Income$-34.9M$-34.9M$-94.0M$-34.3M$-73.4M
EBITDA$70.9M$70.9M$5.4M$75.3M$38.3M
EPS-0.08-0.08-0.21-0.08-0.16
Gross Margin6.9%6.9%7.8%11.4%4.3%
Operating Margin-8.9%-8.9%-7.5%-4.2%-13.0%
Net Margin-4.5%-4.5%-11.5%-4.3%-10.3%
Balance Sheet
Debt/Equity0.050.050.040.040.03
Current Ratio1.851.85———
Cash Flow
Free Cash Flow$-8.6M$-8.6M$-54.3M$-85.2M$-147.6M
Returns
ROE-2.0%-2.0%-5.3%-1.8%-3.9%
Valuation
EV/EBITDA105.87105.87661.4741.2264.19
P/B4.434.432.041.931.61
Growth & Yield
Revenue Growth-4.3%-4.3%1.3%13.5%—
EPS Growth61.9%61.9%-162.5%50.0%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +66.3%

Total return

+66.3%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.21 → -0.08

Residual

+66.3%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+66.3%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.